News

In this week's episode, the panel weighs in on treatments not specifically indicated for COVID-19 treatment, including metformin, and concerns around using medications in this way.

Study shows this could reduce hepatitis C and injection-related infections, with each dollar invested saving $2 in treatment costs.

Governor Newsom declares support for state response as bird flu spreads across the US among dairy cows and humans, with California leading the nation in cases.

143 deaths and 592 cases confirmed in Kwango Province, with concerns about treatment access, drug resistance, and more.

Joseph Zackular, PhD highlights targeting high-risk groups for vaccination and shares insights into the future of mRNA vaccine development for C diff.

Patient-centered innovation amidst evolving regulations and policies is a key strategy.

A study found deploying peers with lived experience in illicit drug use increased the rate of people diagnosed, treated, and cured of the disease.

Prenatal antibiotic use may increase the risk of asthma, food allergies, and obesity, underscoring the need for careful antibiotic stewardship during pregnancy.

The PDUFA date is set for early June, and if approved, it would be the first and only single dose immunization for infants regardless of weight designed to protect them for the duration of their first RSV season.

Joseph Zackular, PhD suggests that mRNA vaccines and monoclonal antibodies could offer more effective treatments for recurrent C difficile infections

Joseph Zackular, PhD, shares insights on his team’s mRNA vaccine research for C difficile, highlighting progress in animal models and future plans for human trials.

Vedanta Biosciences offered further insights on its completed phase 2 trial for its novel therapeutic, VE303.

Health officials are investigating an outbreak called "Dinga Dinga," which causes fever and uncontrollable shaking.

In a study evaluating bulevirtide as monotherapy, investigators found the antiviral to be safe and tolerable following nearly a year of treatment.

This week, evolving COVID-19 inpatient care protocols with ECMO and remdesivir, FDA breakthrough designation for a rapid sepsis test, E coli outbreak linked to iceberg and romaine lettuce, and more.

The development of CRMA-1001, a potential functional cure for chronic hepatitis B and D, is set to enter clinical trials in 2025.

Study finds optimal timing of annual COVID-19 booster depends on regional transmission patterns and if/when breakthrough infection has occurred.

P aeruginosa is found in 11.6% of diabetic foot infection cultures from hot, humid climates.

In this week's episode, the panel discusses therapies and care involving inpatients, including mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and remdesivir.

Sexual transmission was confirmed for nine of the 22 viruses studied, including Ebola, Zika, and mpox, making it a key factor in ongoing disease spread.

Jeanne Marrazzo, MD, MPH, director of NIAID, discusses the mutation changes needed to make human-to-human transmission easier as well as infection prevention strategies.

Alba Azola, MD discusses the challenges of diagnosing and managing Long COVID and its overlap with ME/CFS, emphasizing the need for individualized care and ongoing research.

The federal agency stated there were cases of RSV lower respiratory tract infection (LRTI) post-immunization for 2 of the company’s vaccines, mRNA-1345 and mRNA-1365.

Navigating the long road of Long COVID involves more than recovering from an infection; it requires specialized, multifaceted care to address ongoing and often invisible neurological symptoms.

The ongoing outbreak in the Democratic Republic of Congo is affecting mostly very young children, and has investigators searching for answers.

Interim findings from the STOMP trial reveal that tecovirimat does not significantly accelerate lesion resolution or reduce pain in mild to moderate mpox cases.

Study found that VRE colonization is linked to higher mortality, increased need for mechanical ventilation, and renal replacement therapy, while MRSA and C diff colonization showed less impact.

The MeMed Severity test can determine results within 15 minutes through a blood test and aims to offer treatment guidance with machine learning.

If confirmed by the CDC, these cases would increase the national total of human infections to 60, with 58 already reported in various states.

Focused prevention policies and support systems have shown to reduce HCV prevalence in at-risk groups. Addressing factors like IDU, lack of income, and alcohol misuse through targeted education and interventions is essential to mitigate HCV infection rates locally and globally.